FindTrial
Sign In

Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's Disease

Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-002899-34-GB
Enrollment
Unknown
Registered
2007-06-26
Start date
2007-09-18
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment in Parkinson's Disease

Interventions

Product Name: Sage leaf Pharmaceutical Form: Capsule, hard

Sponsors

Newcastle Upon tyne Hospitals NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: parkinson's disease, mild cognitive impairment (mmse >24 and mattis dementia rating scale =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Dementia according to DSM IV-R. active psychosis. clinically significant depression. use of cholinesterase inhibitors. uncontrolled hypertension.

Design outcomes

Primary

MeasureTime frame
Main Objective: To determineif sage significantly reduces cognitive impairment in people with Parkinson's disease compared to vitamin E;Secondary Objective: ;Primary end point(s): CDR tests of quality and speeds of memory and power of attention—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026